Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice

Liufu Deng, Hua Liang, Byron Burnette, Michael Beckett, Thomas Darga, Ralph R. Weichselbaum, Yang Xin Fu

Research output: Contribution to journalArticle

658 Citations (Scopus)

Abstract

High-dose ionizing irradiation (IR) results in direct tumor cell death and augments tumor-specific immunity, which enhances tumor control both locally and distantly. Unfortunately, local relapses often occur following IR treatment, indicating that IR-induced responses are inadequate to maintain antitumor immunity. Therapeutic blockade of the T cell negative regulator programmed death-ligand 1 (PD-L1, also called B7-H1) can enhance T cell effector function when PD-L1 is expressed in chronically inflamed tissues and tumors. Here, we demonstrate that PD-L1 was upregulated in the tumor microenvironment after IR. Administration of anti-PD-L1 enhanced the efficacy of IR through a cytotoxic T cell-dependent mechanism. Concomitant with IR-mediated tumor regression, we observed that IR and anti-PD-L1 synergistically reduced the local accumulation of tumor-infiltrating myeloid-derived suppressor cells (MDSCs), which suppress T cells and alter the tumor immune microenvironment. Furthermore, activation of cytotoxic T cells with combination therapy mediated the reduction of MDSCs in tumors through the cytotoxic actions of TNF. Our data provide evidence for a close interaction between IR, T cells, and the PD-L1/PD-1 axis and establish a basis for the rational design of combination therapy with immune modulators and radiotherapy.

Original languageEnglish (US)
Pages (from-to)687-695
Number of pages9
JournalJournal of Clinical Investigation
Volume124
Issue number2
DOIs
StatePublished - Feb 3 2014

Fingerprint

Immunity
T-Lymphocytes
Neoplasms
Tumor Microenvironment
Therapeutics
Cell Death
Radiotherapy
Ligands
Recurrence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. / Deng, Liufu; Liang, Hua; Burnette, Byron; Beckett, Michael; Darga, Thomas; Weichselbaum, Ralph R.; Fu, Yang Xin.

In: Journal of Clinical Investigation, Vol. 124, No. 2, 03.02.2014, p. 687-695.

Research output: Contribution to journalArticle

Deng, L, Liang, H, Burnette, B, Beckett, M, Darga, T, Weichselbaum, RR & Fu, YX 2014, 'Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice', Journal of Clinical Investigation, vol. 124, no. 2, pp. 687-695. https://doi.org/10.1172/JCI67313
Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. Journal of Clinical Investigation. 2014 Feb 3;124(2):687-695. https://doi.org/10.1172/JCI67313
Deng, Liufu ; Liang, Hua ; Burnette, Byron ; Beckett, Michael ; Darga, Thomas ; Weichselbaum, Ralph R. ; Fu, Yang Xin. / Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. In: Journal of Clinical Investigation. 2014 ; Vol. 124, No. 2. pp. 687-695.
@article{2bb185d9906649a1bb76b0845bd79953,
title = "Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice",
abstract = "High-dose ionizing irradiation (IR) results in direct tumor cell death and augments tumor-specific immunity, which enhances tumor control both locally and distantly. Unfortunately, local relapses often occur following IR treatment, indicating that IR-induced responses are inadequate to maintain antitumor immunity. Therapeutic blockade of the T cell negative regulator programmed death-ligand 1 (PD-L1, also called B7-H1) can enhance T cell effector function when PD-L1 is expressed in chronically inflamed tissues and tumors. Here, we demonstrate that PD-L1 was upregulated in the tumor microenvironment after IR. Administration of anti-PD-L1 enhanced the efficacy of IR through a cytotoxic T cell-dependent mechanism. Concomitant with IR-mediated tumor regression, we observed that IR and anti-PD-L1 synergistically reduced the local accumulation of tumor-infiltrating myeloid-derived suppressor cells (MDSCs), which suppress T cells and alter the tumor immune microenvironment. Furthermore, activation of cytotoxic T cells with combination therapy mediated the reduction of MDSCs in tumors through the cytotoxic actions of TNF. Our data provide evidence for a close interaction between IR, T cells, and the PD-L1/PD-1 axis and establish a basis for the rational design of combination therapy with immune modulators and radiotherapy.",
author = "Liufu Deng and Hua Liang and Byron Burnette and Michael Beckett and Thomas Darga and Weichselbaum, {Ralph R.} and Fu, {Yang Xin}",
year = "2014",
month = "2",
day = "3",
doi = "10.1172/JCI67313",
language = "English (US)",
volume = "124",
pages = "687--695",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "2",

}

TY - JOUR

T1 - Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice

AU - Deng, Liufu

AU - Liang, Hua

AU - Burnette, Byron

AU - Beckett, Michael

AU - Darga, Thomas

AU - Weichselbaum, Ralph R.

AU - Fu, Yang Xin

PY - 2014/2/3

Y1 - 2014/2/3

N2 - High-dose ionizing irradiation (IR) results in direct tumor cell death and augments tumor-specific immunity, which enhances tumor control both locally and distantly. Unfortunately, local relapses often occur following IR treatment, indicating that IR-induced responses are inadequate to maintain antitumor immunity. Therapeutic blockade of the T cell negative regulator programmed death-ligand 1 (PD-L1, also called B7-H1) can enhance T cell effector function when PD-L1 is expressed in chronically inflamed tissues and tumors. Here, we demonstrate that PD-L1 was upregulated in the tumor microenvironment after IR. Administration of anti-PD-L1 enhanced the efficacy of IR through a cytotoxic T cell-dependent mechanism. Concomitant with IR-mediated tumor regression, we observed that IR and anti-PD-L1 synergistically reduced the local accumulation of tumor-infiltrating myeloid-derived suppressor cells (MDSCs), which suppress T cells and alter the tumor immune microenvironment. Furthermore, activation of cytotoxic T cells with combination therapy mediated the reduction of MDSCs in tumors through the cytotoxic actions of TNF. Our data provide evidence for a close interaction between IR, T cells, and the PD-L1/PD-1 axis and establish a basis for the rational design of combination therapy with immune modulators and radiotherapy.

AB - High-dose ionizing irradiation (IR) results in direct tumor cell death and augments tumor-specific immunity, which enhances tumor control both locally and distantly. Unfortunately, local relapses often occur following IR treatment, indicating that IR-induced responses are inadequate to maintain antitumor immunity. Therapeutic blockade of the T cell negative regulator programmed death-ligand 1 (PD-L1, also called B7-H1) can enhance T cell effector function when PD-L1 is expressed in chronically inflamed tissues and tumors. Here, we demonstrate that PD-L1 was upregulated in the tumor microenvironment after IR. Administration of anti-PD-L1 enhanced the efficacy of IR through a cytotoxic T cell-dependent mechanism. Concomitant with IR-mediated tumor regression, we observed that IR and anti-PD-L1 synergistically reduced the local accumulation of tumor-infiltrating myeloid-derived suppressor cells (MDSCs), which suppress T cells and alter the tumor immune microenvironment. Furthermore, activation of cytotoxic T cells with combination therapy mediated the reduction of MDSCs in tumors through the cytotoxic actions of TNF. Our data provide evidence for a close interaction between IR, T cells, and the PD-L1/PD-1 axis and establish a basis for the rational design of combination therapy with immune modulators and radiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84893876109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893876109&partnerID=8YFLogxK

U2 - 10.1172/JCI67313

DO - 10.1172/JCI67313

M3 - Article

C2 - 24382348

AN - SCOPUS:84893876109

VL - 124

SP - 687

EP - 695

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 2

ER -